Clinical trial · Interventional
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies
NCT00047489CI-TRIAL-00035546completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABT-751 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria * Patients with relapsed or refractory acute leukemias (AML, ALL, MDS \[RAEB, RAEBT\], CMML in transformation with \>/= 10% peripheral blood/bone marrow blasts, CML in blast crisis), and patients with relapsed/refractory or transformed CLL. * Signed informed consent indicating that patients are aware of the investigational nature of this study, and in keeping with the policies of this hospital. * ECOG performance status \</= 2. * Serum direct bilirubin \</= 2 mg/dL, serum SGOT or SGPT \< 3 upper limit of normal, serum creatinine \</= 2 mg/dL, unless considered due to organ leukemic involvement. * Age \> 16 years - a separate Phase I study is being conducted in the pediatric population. Exclusion Criteria * Any severe, concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for study entry. * Pregnant and/or lactating females. * Those with documented sulfonamide allergy should be excluded from study participation.
References
Publications (0)
Data not yet available
No reference posted for this study.